Belatacept for kidney transplant patients with new antibodies
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received a kidney transplant.
- You are an adult.
- You have developed new donor-specific antibodies after transplant, detected by a blood test.
- Your kidney function is stable—no significant recent drop and low protein in urine.
- You have not been treated for these antibodies with therapies like IVIG, rituximab, or plasmapheresis.
- You are not pregnant and are using effective birth control if you can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This study is comparing two medications after kidney transplant: Belatacept and anticalcineurins (like tacrolimus). It looks at how each affects blood vessel health. If you are more than a year post-transplant and have stable kidney function, you may be eligible.
This trial tests whether giving a special type of umbilical cord cell can help treat a form of kidney rejection that hasn't improved with standard antibody treatment. It aims to slow down or stop further kidney damage.
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.